BIOVAXYS Aktie

 

  VANCOUVER, BC, January 15th,2026/ - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to provide an update on 1Q2026 initiatives, including collaborations and non-dilutive funding programs. The Company is pleased to announce that it is participating in a Request for Information (RFI) solicitation issued by the US Government's Biomedical Advanced Research and Development Authority (BARDA) for transformative 'New Vaccine Platforms' that can enable efficient development timelines in response to emerging infectious disease threats.  BARDAs mission is to accelerate medical countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.  The RFI issued by BARDA is the precursor to a subsequent Request for Proposal (RFP), which is issued following BARDA's assessment of novel vaccine platforms submitted during th...

Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology com......

VANCOUVER, BC, December 31st. 2025 / - TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of operating initiatives over the past year following the integration of the DPX™ platform into the BioVaxys business.   The Company's focus continues to drive organic growth by: Expanding its early-stage pipeline by pursuing multiple out licensing opportunities and research collaborations where the Company's DPX platform can address specific needs   Reducing internal risk & the considerable funding requirements of late-stage clinical studies by out-licensing maveropepimut-S (MVP-S) in selected indications seeking a co-development partner for DPX-formulations in infectious diseases.  Re-engagement of clinical trial investigators for continuations of phase 1 studies of DPX formulations   The Company's DPX platform is a major innovation in vaccine development that offers a solution t...

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology co......

   VANCOUVER, BC, December 15, 2025/ – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor.   Dr Stanford was Vice President of R&D at the former IMV Inc, where she and her team were responsible for the development of the DPX™ vaccine portfolio. This included the study of the unique mechanism of action of the DPX platform and its safety, efficacy, and dosing schedules in preclinical models. Under her leadership, Dr. Stanford's team also demonstrated that combining DPX, cyclophosphamide and then PD-1 blockade (using antibodies such as pembrolizumab, Merck's Keytruda™) enhanced immunogenicity and thus efficacy in cancer models.  Dr. Stanford and collaborators have published numerous studies and she is named inventor on multiple patents related to the DPX platform and DPX formulations. This includes patents that explore DPX compos...

  VANCOUVER, BC, November 25, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that, further to its news release dated November 14, 2025, it has issued 1,792,387 common shares in the capital of the Company (each a “Settlement Share”), at a deemed value of $0.23 per Settlement Share, in full and final settlement of accrued and outstanding indebtedness in the aggregate amount of $412,249 (the “Debt Settlement Transaction”).   All securities issued in connection with the Debt Settlement are subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation   This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state se...

   VANCOUVER, BC, November 19, 2025 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Offering”) of 11,311,676 units of the Company (the “Units”) at an issue price of $0.17 per Unit for aggregate gross proceeds of $1,922,984.92.   Each Unit consists of one common share of the Company (“Share”) and one common share purchase warrant (“Warrant”), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance.   The gross proceeds from the Offering are intended to be used to drive more organic pipeline growth by (1) pursuing multiple licensing opportunities and research collaborations with DPX where the Company's platform solutions can address specific needs or gaps, making the Company an attractive 'go-to' partner for targeted im...

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 30, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces an increase to its non-brokered private placement......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 28, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC, Oct. 22, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding unsecured......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 20, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces the conversion of outstanding......

VANCOUVER, BC, Oct. 8, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce that James Tartaglia, PhD, a former top R&D and commercial development executive with Sanofi Vaccines, has been appointed to the......

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it is undertaking a non-brokered private......

The APA Formalized the February 2024 BioVaxys Acquisition of the Former IMV Inc. Assets VANCOUVER, BC, Sept. 29, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce today that the Company and Horizon Technology Finance......

Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen CA09076M1014 BioVaxys Technology Corp. 10.09.2025 CA09076M2004 BioVaxys Technology Corp. 11.09.2025 Tausch 10:1...